2842012-69-3
2842012-69-3
Chemical Structure
BAL-0028
- CAS No.: 2842012-69-3
- Formula:C24H22FN3O2
- Molecular Weight:403.45
InChIKey: VTZLXMQBXAOBJF-UHFFFAOYSA-N
SMILES: CN(C(C1=CC(OCC)=C(C2=CC(F)=CC=C2)C=C1)=O)CC3=C4C(C=NN4)=CC=C3
Biological Activity: BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BAL-0028 | 99.86% | BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CRT5 | 98.70% | CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PF-05105679 | 99.88% | PF-05105679, a chemical probe, is an orally active and selective TRPM8 antagonist with an IC50 of 103 nM. PF-05105679 has the potential for cold-related pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PPY-A | 98.02% | PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba?F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WWL123 analogue-1 | 98.04% | WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective ABHD6 inhibitor with an IC50 of 430 nM. WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FGFR2-IN-1 | 99.28% | FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NLRP3-IN-35 | NLRP3-IN-35 (compound 11) is an NLRP3 inhibitor (IC50 < 1 μM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NLRP3-IN-36 | NLRP3-IN-36 (Compound 111) is an NLRP3 inhibitor (IC50 <1 μM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NLRP3-IN-80 | 99.43% | NLRP3-IN-80 (Compound 1) is an NLRP3 inhibitor that can be used for the study of inflammaging. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atg4B activator-1 | Atg4B activator-1 (Compound 16a) is an allosteric, selective, and orally active ATG4B activator with a Kd of 0.2199 μM. Atg4B activator-1 binds to the allosteric pocket of ATG4B and induces conformational changes. Atg4B activator-1 induces Autophagy. Atg4B activator-1 inhibits the proliferation and migration of triple-negative breast cancer cells. Atg4B activator-1 can be used in studies related to triple-negative breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2,2''-Dimethoxy-[1,1':4',1''-terphenyl]-4,4''-dicarboxylic acid | 2,2''-Dimethoxy-[1,1':4',1''-terphenyl]-4,4''-dicarboxylic acid is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
